Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial

Annemiek Visser, Judith B Prins, Nicoline Hoogerbrugge, Hanneke W M van Laarhoven, Annemiek Visser, Judith B Prins, Nicoline Hoogerbrugge, Hanneke W M van Laarhoven

Abstract

Background: BRCA mutation carriers have a 40-80% life-time risk of developing breast cancer. They may opt for yearly breast cancer surveillance or for prophylactic mastectomy. Both options show increased survival rates. It is a complex choice to be made between these two options. As a result most women experience high levels of distress and high needs for information. To fulfill the needs for psychosocial support and information we have introduced group medical consultations (GMCs). A GMC provides individual medical visits conducted within a group. This 90 minute group-visit with 8-12 patients gives patients the opportunity to spend more time with their clinician and a behavioral health professional and learn from other patients experiencing similar topics. However, it should be noted that group sessions may increase fear in some patients or influence their decision making.

Methods/design: In this randomized controlled trial, 160 BRCA mutation carriers diagnosed maximally 2 years ago are recruited from the Radboud University Nijmegen Medical Centre. Participants are randomized in a 1:1 ratio to either the GMC intervention group (onetime participation in a GMC instead of a standard individual visit) or to a usual care control group. Primary outcome measures are empowerment and psychological distress (SCL 90). Secondary outcome measures are fear of cancer, information needs before the consultation and the received information, self-examination of the breasts, patient satisfaction, quality of life and cost-effectiveness. Data are collected via self-reported questionnaires 1 week before the visit, and at 1 week and at 3 months follow-up. A pilot study was conducted to test all procedures and questionnaires.

Discussion: The possibility for interaction with other BRCA mutation carriers within a medical visit is unique. This study will assess the effectiveness of GMCs for BRCA mutation carriers to improve empowerment and decrease distress compared to individual visits. If GMCs prove to be effective and efficient, implementation of GMCs in regular care for BRCA mutation carriers will be recommended.

Trial registration: ClinicalTrials.gov NCT01329068.

Figures

Figure 1
Figure 1
Flow-chart of the study.

References

    1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333. doi: 10.1200/JCO.2006.09.1066.
    1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American journal of human genetics. 2003;72(5):1117–1130. doi: 10.1086/375033.
    1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (New York, NY. 2003;302(5645):643–646. doi: 10.1126/science.1088759.
    1. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. Jama. 2004;292(11):1317–1325. doi: 10.1001/jama.292.11.1317.
    1. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. The New England journal of medicine. 2004;351(5):427–437. doi: 10.1056/NEJMoa031759.
    1. Rijnsburger AJ, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. International journal of cancer. 2004;110(5):756–762. doi: 10.1002/ijc.20143.
    1. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine. 2001;345(3):159–164. doi: 10.1056/NEJM200107193450301.
    1. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062. doi: 10.1200/JCO.2004.04.188.
    1. Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Annals of surgery. 2010;251(3):488–492. doi: 10.1097/SLA.0b013e3181c3c36d.
    1. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–231. doi: 10.1200/JCO.2009.22.7991.
    1. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. International journal of cancer. 2004;112(3):357–364. doi: 10.1002/ijc.20429.
    1. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–2335. doi: 10.1200/JCO.2004.04.033.
    1. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. British journal of cancer. 2005;93(3):287–292. doi: 10.1038/sj.bjc.6602703.
    1. Menke-Pluymers MB, Seynaeve C, van Geel AN, Klijn JG, Meijers-Heijboer EJ, Eggermont AM. Preventief chirugisch ingrijpen bij erfelijke belasting voor borstkanker. Ned Tijdschr Geneeskd. 2005;149:2663–2667.
    1. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23(19):4275–4286. doi: 10.1200/JCO.2005.10.080.
    1. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Moller P, Weitzel J, Sun P, Narod SA. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093–1097. doi: 10.1200/JCO.2007.12.6078.
    1. Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clinical genetics. 2010;78(5):411–417. doi: 10.1111/j.1399-0004.2010.01499.x.
    1. Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, Surdam J, Orinion E, Slominski-Caster S, Watson P, Lerman C, Tonin P, Lenoir G, Serova O, Narod S. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 1997;79(11):2219–2228. doi: 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>;2-Y.
    1. van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol. 2006;24(22):3672–3677. doi: 10.1200/JCO.2005.03.7259.
    1. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21(20):3867–3874. doi: 10.1200/JCO.2003.10.100.
    1. Meiser B, Butow P, Friedlander M, Schnieden V, Gattas M, Kirk J, Suthers G, Haan E, Tucker K. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol. 2000;18(11):2250–2257.
    1. Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C. Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hereditary cancer in clinical practice. 2009;7(1):6.. doi: 10.1186/1897-4287-7-6.
    1. Landsbergen KM, Brunner HG, Manders P, Hoogerbrugge N, Prins JB. Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress. Genetic counseling (Geneva, Switzerland) 2010;21(4):423–437.
    1. Haddad S, Potvin L, Roberge D, Pineault R, Remondin M. Patient perception of quality following a visit to a doctor in a primary care unit. Family practice. 2000;17(1):21–29. doi: 10.1093/fampra/17.1.21.
    1. Walker MS, Ristvedt SL, Haughey BH. Patient care in multidisciplinary cancer clinics: does attention to psychosocial needs predict patient satisfaction? Psycho-oncology. 2003;12(3):291–300. doi: 10.1002/pon.651.
    1. Uitterhoeve R, Bensing J, Dilven E, Donders R, deMulder P, van Achterberg T. Nurse-patient communication in cancer care: does responding to patient's cues predict patient satisfaction with communication. Psycho-oncology. 2009;18(10):1060–1068. doi: 10.1002/pon.1434.
    1. Jaber R, Braksmajer A, Trilling JS. Group visits: a qualitative review of current research. J Am Board Fam Med. 2006;19(3):276–290. doi: 10.3122/jabfm.19.3.276.
    1. Zantinge EM, Seesing FM, Tol FE, Raats CJ, Spreeuwenberg PM, van Dulmen AM. Shared Medical Appointments: experiences of patients and care givers. Nederlands tijdschrift voor geneeskunde. 2009;153:A828.
    1. Meehan KR, Hill JM, Root L, Kimtis E, Patchett L, Noffsinger EB. Group medical appointments: organization and implementation in the bone marrow transplantation clinic. Supportive cancer therapy. 2006;3(2):84–90. doi: 10.3816/SCT.2006.n.003.
    1. Beck A, Scott J, Williams P, Robertson B, Jackson D, Gade G, Cowan P. A randomized trial of group outpatient visits for chronically ill older HMO members: the Cooperative Health Care Clinic. Journal of the American Geriatrics Society. 1997;45(5):543–549.
    1. Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, Watson R, Swain BE, Selby JV, Javorski WC. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes care. 1999;22(12):2011–2017. doi: 10.2337/diacare.22.12.2011.
    1. Scott JC, Conner DA, Venohr I, Gade G, McKenzie M, Kramer AM, Bryant L, Beck A. Effectiveness of a group outpatient visit model for chronically ill older health maintenance organization members: a 2-year randomized trial of the cooperative health care clinic. Journal of the American Geriatrics Society. 2004;52(9):1463–1470. doi: 10.1111/j.1532-5415.2004.52408.x.
    1. Noffsinger EB, Atkins TN. Assessing a group medical appointment program: a case study at Sutter Medical Foundation. Group Pract J. 2001;48:42–49.
    1. Seesing FM, Raats I. Gezamenlijk Medisch Consult. Een praktische handleiding. Houten: Bohn Stafleu; 2009.
    1. Trento M, Passera P, Bajardi M, Tomalino M, Grassi G, Borgo E, Donnola C, Cavallo F, Bondonio P, Porta M. Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia. 2002;45(9):1231–1239. doi: 10.1007/s00125-002-0904-8.
    1. Blumenfeld A, Tischio M. Center of excellence for headache care: group model at Kaiser Permanente. Headache. 2003;43(5):431–440. doi: 10.1046/j.1526-4610.2003.03087.x.
    1. Yehle KS, Sands LP, Rhynders PA, Newton GD. The effect of shared medical visits on knowledge and self-care in patients with heart failure: a pilot study. Heart Lung. 2009;38(1):25–33. doi: 10.1016/j.hrtlng.2008.04.004.
    1. Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, Coleman EA. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes care. 2001;24(4):695–700. doi: 10.2337/diacare.24.4.695.
    1. Clancy DE, Brown SB, Magruder KM, Huang P. Group visits in medically and economically disadvantaged patients with type 2 diabetes and their relationships to clinical outcomes. Topics in health information management. 2003;24(1):8–14.
    1. Clancy DE, Cope DW, Magruder KM, Huang P, Salter KH, Fields AW. Evaluating group visits in an uninsured or inadequately insured patient population with uncontrolled type 2 diabetes. The Diabetes educator. 2003;29(2):292–302. doi: 10.1177/014572170302900220.
    1. Clancy DE, Cope DW, Magruder KM, Huang P, Wolfman TE. Evaluating concordance to American Diabetes Association standards of care for type 2 diabetes through group visits in an uninsured or inadequately insured patient population. Diabetes care. 2003;26(7):2032–2036. doi: 10.2337/diacare.26.7.2032.
    1. Noffsinger EB, Scott J. Practical tips for establishing successful group vist programs. Group Pract J. 2000;49:24–37.
    1. Noffsinger EB. Will Drop-In Group Medical Appointments (DIGMAs) Work in Practice? The permanente Journal. 1999;3:58–67.
    1. Bronson DL, Maxwell RA. Shared medical appointments: increasing patient access without increasing physician hours. Cleveland Clinic journal of medicine. 2004;71(5):369–370, 372, 374 passim. doi: 10.3949/ccjm.71.5.369.
    1. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, Spinhoven P, van der Meer JW. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet. 2001;357(9259):841–847. doi: 10.1016/S0140-6736(00)04198-2.
    1. Landsbergen KM, Prins JB, Kamm YJ, Brunner HG, Hoogerbrugge N. Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years. Familial cancer. 2010;9(2):213–220. doi: 10.1007/s10689-009-9311-3.
    1. van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol. 2008;26(14):2358–2363. doi: 10.1200/JCO.2006.10.5494.
    1. van de Berg S, Gielissen MF, Prins JB. Validation of an empowerment questionnaire in breast cancer survivors. 12th World Congress of Psycho-Oncology. 2010.
    1. Arrindell WA, Ettema JHM. Symptom Checklist-90; Handleiding bij een multidimensionele psychopathologie-indicator. Lisse: Swets & Zeitlinger B.V; 2003.
    1. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994;12(4):843–850.
    1. Hopwood P, Shenton A, Lalloo F, Evans DG, Howell A. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. Journal of medical genetics. 2001;38(2):139.. doi: 10.1136/jmg.38.2.139.
    1. van Campen C, Sixma HJ, Kerssens JJ, Peters L, Rasker JJ. Assessing patients' priorities and perceptions of the quality of health care: the development of the QUOTE-Rheumatic-Patients instrument. British journal of rheumatology. 1998;37(4):362–368. doi: 10.1093/rheumatology/37.4.362.
    1. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol. 2007;25(32):5082–5086. doi: 10.1200/JCO.2007.11.3183.
    1. Luo N, Fones CS, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore. Qual Life Res. 2005;14(4):1181–1186. doi: 10.1007/s11136-004-4782-z.
    1. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res. 1993;2(4):287–295. doi: 10.1007/BF00434800.
    1. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–2768.
    1. Horn EK, van Benthem TB, Hakkaart-van Roijen L, van Marwijk HW, Beekman AT, Rutten FF, van der Feltz-Cornelis CM. Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial. BMC health services research. 2007;7:28. doi: 10.1186/1472-6963-7-28.
    1. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol. 2006;24(30):4882–4887. doi: 10.1200/JCO.2006.06.8270.
    1. Kessels RP. Patients' memory for medical information. Journal of the Royal Society of Medicine. 2003;96(5):219–222. doi: 10.1258/jrsm.96.5.219.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere